[ad_1]
Pfizer along with BioNTech, the two companies that are taking the most decisive steps to tackle the pandemic, are applying for emergency approval for the coronavirus vaccine.
The company announced that it would apply to the Food and Drug Administration for an immediate emergency permit. use of the vaccine so that its distribution can begin in the next month.
The news comes a few days after the company announced the 95% effectiveness of the vaccine, but also a few hours after the statements of the Greek CEO of Pfizer, Albert Bourlas, who clarified that the first doses will begin to be distributed immediately afterwards. your approval.
Of course, until FDA approval of the vaccine, if it comes, will take a few weeks, however, as the company appears poised to distribute the first doses in December.
Previously, Albert Burla gave an interview to TIME, talking about his expectations and the disposition of the company, while after the end of the interview he posted on Twitter, describing in a few words the “journey” that took place until the production and Request for approval.
In fact, the Greek CEO of the American company did not hide his satisfaction and pride, while speaking for a historic moment.
Last Thursday, the Director of BioNTech, andseemed optimistic about approval of the vaccine in the next month.
The United States plans to begin vaccinating Americans immediately, while in relation to the price of the vaccine, the company spoke of “affordable prices,” and Mr. Bourlas recently stated that the mood “will not be for the purpose of profit “in the poorest countries.
“Our work to provide a safe and effective vaccine has never been more urgent as we continue to see a worrying increase in the number of COVID-19 cases around the world. “Introducing ourselves to the US represents a critical milestone in our journey to deliver the COVID-19 vaccine around the world, and we now have a more complete picture of the efficacy and safety profile of our vaccine, giving us confidence in your potential. “ Albert Burla said.
““Authorizing emergency use in the United States is a critical step in making the vaccine available to the world population as soon as possible.” said Ugur Sahin, co-founder of BioNTech. “We plan to continue working with regulators around the world to enable the rapid distribution of our vaccine around the world. “As a company located in Germany, in the heart of Europe, our interactions with the European Medicines Agency (EMA) are of particular importance to us and we constantly provide data as part of the ongoing scrutiny process.” pointed further.
Read the news from Greece and the world, with the reliability and validity of News247.gr.
[ad_2]
